DEC1/STRA13 is a bHLH type transcriptional regulator involved with immune regulation, hypoxia response and carcinogenesis. We recently demonstrated that STRA13 interacts with STAT3 in the transcriptional activation of STAT-dependent promoters. Here, we pursue STRA13 involvement in the JAK/STAT pathway by studying its role in STAT1 expression. First, we showed that VHL deficiency or HIF-1 activation resulted in the repression of endogenous STAT1 mediated by STRA13. We then characterized the STAT1 proximal promoter to assess its response to STRA13 by transient coexpression in a luciferase reporter assay. Using sequential truncation and site-directed mutagenesis of the STAT1 promoter with STRA13 deletion constructs, we showed that the STRA13 C-terminal trans-activation domain, which is known to bind HDAC1, mostly determines the repressive activity. Involvement of HDAC activity in STAT1 regulation was validated by TSA inhibition and chromatin immunoprecipitation (ChIP) assay. Thus, we demonstrate that STRA13-mediated repression of STAT1 transcription utilizes an HDAC1-dependent mechanism. Furthermore, we show that targets of unphosphorylated STAT1, such as antigen presenting genes and CASP1, are also repressed by hypoxia possibly through the same STRA13-mediated mechanism. Thus, the newly discovered link between HIF-1 and STAT1 reveals a previously unknown role of STRA13 in hypoxia and carcinogenesis. Oncogene Shuai and Liu, 2003). STAT1 and STAT3 are that two principal signal transducers in this pathway that serve disparate physiological roles through transcriptional activation of different targets (Qing and Stark, 2004). In carcinogenesis, these proteins have opposite effects on cell growth and survival; while STAT3 is an oncogene (Bromberg et al., 1999), STAT1 possesses tumor suppressor properties (Kaplan et al., 1998;Bromberg and Darnell, 2000). STAT1's major functions, executed through the IFNg-induced Y701 phosphorylation, are inhibition of proliferation, activation of antimicrobial and antiviral responses, and induction of antitumor immune defense (Shuai et al., 1996;Kaplan et al., 1998;Stark et al., 1998). Recent data suggest that unphosphorylated STAT1 may also play an important role in the regulation of constitutive expression of certain genes (Kumar et al., 1997;Chatterjee-Kishore et al., 2000;Meyer et al., 2002).In this study, we identify STAT1 as a transcriptional target of STRA13, investigate the molecular mechanisms of STRA13 activity on the STAT1 promoter, and assess the downstream effects of this activity.
Results
Introduction of VHL in clear cell carcinoma cells stimulates STAT1 expressionOur previous study revealed functional interaction between a VHL/HIF-1 target STRA13 and STAT3 (Ivanova et al., 2004). To find out if STRA13 can be associated with other constituents of the JAK/STAT pathway, we took advantage of cell lines with different VHL status. The original clear cell carcinoma cell lines UM-RC-6 and 786-0 contain frameshift mutations in the remaining VHL allele that make aberrant proteins...